Literature DB >> 19874860

Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.

Malou Henriksen-Lacey1, Vincent W Bramwell, Dennis Christensen, Else-Marie Agger, Peter Andersen, Yvonne Perrie.   

Abstract

The mechanism behind the immunostimulatory effect obtained with the cationic liposomal vaccine adjuvant DDA:TDB remains unclear. One of the proposed hypotheses is the 'depot effect' in which the liposomal carrier helps to retain the antigen at the injection site thereby increasing the time of vaccine exposure to the immune cells. In the present study we devise a method to quantify the in vivo movement of liposomes and vaccine antigen using the radioisotopes H(3) and I(125) respectively. H(3)-labeled liposomes composed of dimethyldioctadecylammonium bromide (DDA) or an 8:1 molar ratio of DDA and trehalose 6,6-dibehenate (TDB) were administered in combination with I(125)-labeled Ag85B-ESAT-6 antigen, both via intramuscular and subcutaneous injection to mice. Furthermore characterisation of the liposomal system in simulated in vivo conditions was undertaken. Our results show that this dual-labeling technique is functional and reproducible. The administration of Ag85B-ESAT-6 without a liposomal carrier leads to rapid dissemination of the antigen from the site of injection. The administration of Ag85B-ESAT-6 together with either DDA or DDA:TDB liposomes however leads to deposition of the antigen at the injection site with detectable levels still being present 14 days post injection. Neither the incorporation of TDB nor the route of injection had any significant influence on the depot effect of DDA-based liposomes. The presence of TDB in DDA liposomes improves draining of liposomes to the lymph node in addition to increasing monocyte influx to the site of injection as highlighted by the intensive blue colouring of the injection site after pontamine blue staining of phagocytic cells in vivo. Our findings provide conclusive evidence for a cationic liposome-mediated deposition of antigen at the injection site with improved monocyte infiltration. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874860     DOI: 10.1016/j.jconrel.2009.10.022

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  49 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

3.  Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Authors:  Pernille Nordly; Else Marie Agger; Peter Andersen; Hanne Mørck Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

Review 4.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

Review 5.  Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease.

Authors:  Katherine A Roach; Aleksandr B Stefaniak; Jenny R Roberts
Journal:  J Immunotoxicol       Date:  2019-12       Impact factor: 3.000

Review 6.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

7.  Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.

Authors:  Dennis Christensen; Thomas Lindenstrøm; Gijsbert van de Wijdeven; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

Review 8.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

9.  Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.

Authors:  Mette Hamborg; Lene Jorgensen; Anders Riber Bojsen; Dennis Christensen; Camilla Foged
Journal:  Pharm Res       Date:  2012-09-06       Impact factor: 4.200

10.  Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells.

Authors:  Randip Kaur; Jili Chen; Amina Dawoodji; Vincenzo Cerundolo; Yoel R Garcia-Diaz; Justyna Wojno; Liam R Cox; Gurdyal S Besra; Behfar Moghaddam; Yvonne Perrie
Journal:  J Pharm Sci       Date:  2011-01-31       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.